
    
      Only one subject was able to be enrolled. Given enrollment challenges to identify additional
      appropriate subjects, discussion was held with the Japan Pharmaceuticals and Medical Devices
      Agency (PMDA) and it was agreed with the PMDA to terminate this study. The study was
      terminated on December 14, 2010. The study was not terminated due to any safety findings.
    
  